A share price of Corcept Therapeutics Inc [CORT] is currently trading at $36.53, down -1.27%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CORT shares have gain 4.97% over the last week, with a monthly amount drifted -55.98%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on December 31, 2025, when Wolfe Research downgraded its rating to an Underperform but kept the price target unchanged to $30 for it. On November 18, 2025, Wolfe Research initiated with a Peer Perform rating. Truist upgraded its rating to a Buy and increased its price target to $38 on November 06, 2023. SVB Securities initiated its recommendation with a Market Perform and recommended $25 as its price target on April 11, 2023. Piper Sandler started tracking with an Overweight rating for this stock on April 04, 2023, and assigned it a price target of $27. In a note dated February 15, 2023, Jefferies downgraded a Hold rating on this stock and revised its target price from $35 to $22.
Corcept Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $32.99 and $117.33. Currently, Wall Street analysts expect the stock to reach $72.8 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $36.53 at the most recent close of the market. An investor can expect a potential return of 99.29% based on the average CORT price forecast.
Analyzing the CORT fundamentals
Trailing Twelve Months sales for Corcept Therapeutics Inc [NASDAQ:CORT] were 741.17M which represents 13.75% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.16 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.94 points at the first support level, and at 35.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.31, and for the 2nd resistance point, it is at 38.09.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Corcept Therapeutics Inc [NASDAQ:CORT] is 3.14. As well, the Quick Ratio is 3.07, while the Cash Ratio is 0.73. Considering the valuation of this stock, the price to sales ratio is 5.18, the price to book ratio is 6.08 and price to earnings (TTM) ratio is 41.74.
Transactions by insiders
Recent insider trading involved Guyer William, Chief Development Officer, that happened on Jan 06 ’26 when 20000.0 shares were sold. Officer, Guyer William completed a deal on Jan 06 ’26 to buy 20000.0 shares. Meanwhile, Chief Development Officer Guyer William sold 20000.0 shares on Dec 02 ’25.
